13 completed. 13 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 13 |
| Phase 2 | 1 | Completed 1 |
Follow Glomerulonephritis, IGA: new trials by email Literature Review of Glomerulonephritis, IGA trials Research Report on Glomerulonephritis, IGA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301 Nefecon - Primary Immunoglobulin a Nephropathy (IgAN) | Phase 3 | Completed | Everest Medicines (Singapore) Pte. Ltd. | 21 | 2022-12-09 | 2024-11-12 |
| Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients Placebo, LNP023 - IgA Nephropathy | Phase 3 | Completed | Novartis Pharmaceuticals | 517 | 2021-01-25 | 2026-11-04 |
| Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE) Nefecon 16mg daily - Primary IgA Nephropathy | Phase 3 | Completed | Calliditas Therapeutics AB | 119 | 2020-11-17 | 2025-02-10 |
| A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy sparsentan, irbesartan, Dapagliflozin - Immunoglobulin A Nephropathy | Phase 3 | Completed | Travere Therapeutics, Inc. | 406 | 2018-12-11 | 2026-10-14 |
| Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy Nefecon, Placebo oral capsule - Primary IgA Nephropathy | Phase 3 | Completed | Calliditas Therapeutics AB | 365 | 2018-09-05 | 2024-12-03 |
| Treatment of IgA Nephropathy According to Renal Lesions corticotherapy, Renin Angiotensin system (RAS) blockade or Inhibitors of sodium glucose transporter 2 (SGLT2i) - IgA Nephropathy | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 62 | 2018-02-20 | 2025-11-20 |
| Efficacy and Safety of Losartan in Children With Ig A Nephropathy Losartan - Glomerulonephritis, IGA | Phase 3 | Completed | Seoul National University Hospital | 37 | 2014-10-01 | 2018-10-10 |
| BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration Blisibimod, Placebo - IgA Nephropathy | Phase 2 / Phase 3 | Completed | Anthera Pharmaceuticals | 57 | 2013-06-01 | 2017-09-18 |
| Aliskiren for Immunoglobulin A (IgA) Nephropathy Aliskiren, Placebo - IgA Nephropathy | Phase 3 | Completed | Chinese University of Hong Kong | 22 | 2009-04-01 | 2012-12-04 |
| Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy supportive therapy with: ACE-inhibitor / ARB / Statin, supportive and immunosuppressive therapy - IgA Nephropathy | Phase 3 | Completed | RWTH Aachen University | 148 | 2008-02-01 | 2015-09-22 |
| Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy Omega-3 fatty acid ethylester90 - IgA Nephropathy | Phase 3 | Completed | Kuhnil Pharmaceutical Co., Ltd. | 152 | 2007-11-01 | 2012-09-27 |
| Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN) irbesartan, methylprednisolone (MP) or prednisone (pred), mycophenolate mofetil (MMF) - IgA Nephropathy | Phase 3 | Completed | Sun Yat-sen University | 151 | 2007-09-01 | 2019-12-03 |
| Steroids and Azathioprine in Advanced IgAN methylprednisolone, azathioprine, prednisone - IgA Nephropathy, Chronic Kidney Disease | Phase 3 | Completed | A. Manzoni Hospital | 46 | 1999-12-01 | 2011-07-13 |
Proteinuria (4) · Glomerulonephritis (1) · Kidney Diseases (1) · Renal Insufficiency (1) · Renal Insufficiency, Chronic (1)
Autoimmune Diseases (13) · Female Urogenital Diseases (13) · Female Urogenital Diseases and Pregnancy Complications (13) · Immune System Diseases (13) · Male Urogenital Diseases (13) · Nephritis (13) · Urogenital Diseases (13) · Urologic Diseases (13) · Glomerulonephritis (12) · Kidney Diseases (12) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Urination Disorders (4) · Urological Manifestations (4) · Chronic Disease (1)
Irbesartan (2) · Methylprednisolone (2) · Prednisone (2) · AMG623 peptibody (1) · Adenosine Triphosphate (1) · Azathioprine (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Immunosuppression Therapy (1) · Losartan (1) · Methylprednisolone Hemisuccinate (1) · Mycophenolic Acid (1) · Omacor (1) · Palliative Care (1) · Renin-Angiotensin System (1) · aliskiren (1)
Calliditas Therapeutics AB (2) · A. Manzoni Hospital (1) · Anthera Pharmaceuticals (1) · Assistance Publique - Hôpitaux de Paris (1) · Chinese University of Hong Kong (1) · Everest Medicines (Singapore) Pte. Ltd. (1) · Kuhnil Pharmaceutical Co., Ltd. (1) · Novartis Pharmaceuticals (1) · RWTH Aachen University (1) · Seoul National University Hospital (1) · Sun Yat-sen University (1) · Travere Therapeutics, Inc. (1)
South Korea (7) · Germany (6) · Czechia (5) · France (5) · United Kingdom (5) · Australia (4) · Belgium (4) · Italy (4) · Spain (4) · Taiwan (4) · United States (4) · Argentina (3) · Canada (3) · China (3) · Hong Kong (3)
Anping Xu, MD (1) · Byung-Joo Park, MD,PhD,FISPE (1) · Hee Gyung Kang, Ph.D (1) · Jicheng Lv, Doctor (1) · Jinli Zhang, MD (1) · Juergen Floege, Prof. Dr. (1) · Junzhou Fu, MD (1) · Khalil El Karoui (1) · Krassimir Mitchev, MD (1) · Li Hao, MD (1) · Menghua Chen, MD (1) · Qinkai Chen, MD (1)
PMID 38299639, PMID 26032537, PMID 37772889, PMID 38864363, PMID 18587715, PMID 23675422, PMID 26630142, PMID 35675911, PMID 36270561, PMID 36685528, PMID 37015244, PMID 37254256, PMID 37591292, PMID 37914086, PMID 37931634, PMID 39453772, PMID 39724565, PMID 40627446, PMID 41428405, PMID 41661687, PMID 41910396, PMID 42909451
2016 (1), 2017 (1), 2023 (1)